Creative Planning Gilead Sciences, Inc. Call Options Transaction History

Creative Planning

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2020 Jan 29, 2021	BUY	$56.65 - $64.55 $28,325 - $32,275	500 Added 500.0%	600 $1,000
Q2 2020 Jul 23, 2020	SELL	$72.34 - $84.0 $21,702 - $25,200	-300 Reduced 75.0%	100 $1,000
Q1 2020 May 05, 2020	SELL	$62.63 - $80.22 $62,630 - $80,220	-1,000 Reduced 71.43%	400 $2,000
Q1 2019 Apr 24, 2019	SELL	$62.53 - $70.05 $106,301 - $119,085	-1,700 Reduced 54.84%	1,400 $4,000
Q4 2018 Feb 01, 2019	SELL	$60.54 - $79.0 $30,270 - $39,500	-500 Reduced 13.89%	3,100 $5,000
Q3 2018 Oct 25, 2018	BUY	$71.28 - $78.92 $135,432 - $149,948	1,900 Added 111.76%	3,600 $30,000
Q2 2018 Jul 20, 2018	SELL	$64.88 - $75.68 $12,976 - $15,136	-200 Reduced 10.53%	1,700 $3,000
Q1 2018 Apr 18, 2018	BUY	$72.84 - $88.8 $138,396 - $168,720	1,900 New	1,900 $10,000

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

Stay updated on Creative Planning with notifications on news.